rethinkPeptides Search
Menu
Study breakdown

Community Perspectives on GLP-1 Drugs: What Patients Really Think

evidence
The takeaway

Qualitative study of community perspectives and experiences with GLP-1 drugs captures patient voices on access, expectations, experiences, and concerns.

Key finding

Qualitative study of community perspectives and experiences with GLP-1 drugs captures patient voices

What the researchers found

Qualitative study of community perspectives and experiences with GLP-1 drugs captures patient voices on access, expectations, experiences, and concerns.

Why it matters

Relevant to peptide therapeutics.

How the study worked

In publication.

What this study cannot tell us

In publication.

How to read the evidence

Based on design.

When this study was published

Published in 2025.

The bigger picture

Advances peptide evidence.

Questions still open

  • Long-term implications?
  • Evidence comparison?
  • Next steps?

Common questions

What does this mean?
Qualitative study of community perspectives and experiences with GLP-1 drugs captures patient voices on access, expectations, experiences, and concerns.
How reliable?
Consult publication.

Read the original research

What are community perspectives and experiences around GLP-1 receptor agonist medications for weight loss? A cross-sectional survey study in the UK.

BMJ public health, 3(2), e002519

Citation

Auerbach, Nadja; Liu, Vivian N; Huang, David Roy; Clift, Ashley Kieran; Al-Ammouri, Mahmoud; El-Osta, Austen. (2025). What are community perspectives and experiences around GLP-1 receptor agonist medications for weight loss? A cross-sectional survey study in the UK.. BMJ public health, 3(2), e002519. https://doi.org/10.1136/bmjph-2024-002519